Tazorac is a drug owned by Allergan Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 07, 2014. Details of Tazorac's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5914334 | Stable gel formulation for topical treatment of skin conditions |
Jun, 2014
(10 years ago) |
Expired
|
| US6258830 | Stable gel formulation for topical treatment of skin conditions |
Jun, 2014
(10 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Tazorac is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tazorac's family patents as well as insights into ongoing legal events on those patents.
Tazorac's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Tazorac's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 07, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tazorac Generics:
Tazarotene is the generic name for the brand Tazorac. 5 different companies have already filed for the generic of Tazorac, with Cosette having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Tazorac's generic
About Tazorac
Tazorac is a drug owned by Allergan Inc. It is used for topical treatment of skin conditions. Tazorac uses Tazarotene as an active ingredient. Tazorac was launched by Allergan in 1997.
Market Authorisation Date:
Tazorac was approved by FDA for market use on 13 June, 1997.
Active Ingredient:
Tazorac uses Tazarotene as the active ingredient. Check out other Drugs and Companies using Tazarotene ingredient
Treatment:
Tazorac is used for topical treatment of skin conditions.
Dosage:
Tazorac is available in gel form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.05% | GEL | Prescription | TOPICAL |
| 0.1% | GEL | Prescription | TOPICAL |